PN: A112227T

COMPONENTS

45x Ab-conjugated beads (S4P4 - human IP-10 Ab-bead). PN: A112227TA. One vial containing 35 µL of anti-human IP-10 conjugated to AimPlex Bead S4P4

25x Biotin-detection Ab (human IP-10 Biotin-dAb). PN: A112227TB. One vial containing 35 µL of biotinylated anti-human IP-10.

Lyophilized Standard Mix-Human Group 1 Panel B. PN: HG10011. One vial containing lyophilized recombinant Eotaxin, IL-1β, IL-1RA, IL-8, IL-12p70, IL-22, IP-10, MCP-1, MCP-3, and RANTES. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits. 

STORAGE:  2-8 C in the dark.

IMPORTANT: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

APPLICATION: Optimal antibody pair and antigen standard for assaying human CXCL10/IP-10.  Can be multiplexed with other analytes in Human Group 1.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001T) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

Sensitivity (LOD): < 3 pg/mL

Quantitation range:

LLOQ: <10 pg/mL

ULOQ: > 2,000 pg/mL

Standard dose recovery: 70-130%

Intra-assay CV: < 10%

Inter-assay CV: < 20%

Cross-reactivity of analytes in Human Group 1: Negligible

Sample volume: 15 µL/test

Description:

C-X-C motif chemokine 10 (CXCL10), also known as Interferon gamma-induced protein 10 (IP-10) or small-inducible cytokine B10, is a small cytokine belonging to the CXC chemokine family. CXCL10 is secreted by several cell types in response to IFN-γ. These cell types include monocytes, endothelial cells and fibroblasts. CXCL10 has been attributed to several roles, such as chemo-attraction for monocytes/macrophages, T cells, NK cells, and dendritic cells, promotion of T cell adhesion to endothelial cells, antitumor activity, and inhibition of bone marrow colony formation and angiogenesis. This chemokine elicits its effects by binding to the cell surface chemokine receptor CXCR3. Diseases associated with CXCL10 include peritoneal carcinoma and endotheliitis. Baseline pre-treatment plasma levels of CXCL10 are elevated in patients chronically infected with hepatitis C virus (HCV) of genotypes 1 or 4 who do not achieve a sustained viral response (SVR) after completion of antiviral therapy. Diseases associated with CXCL10 include peritoneal carcinoma and endotheliitis.

References:

1.       Luster AD, Unkeless JC, Ravetch JV (1985). "Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins". Nature 315 (6021): 672–6. doi:10.1038/315672a0. PMID 3925348.

2.       Luster AD, Jhanwar SC, Chaganti RS, Kersey JH, Ravetch JV (May 1987). "Interferon-inducible gene maps to a chromosomal band associated with a (4;11) translocation in acute leukemia cells". Proc. Natl. Acad. Sci. U.S.A. 84 (9): 2868–71. doi:10.1073/pnas.84.9.2868. PMC 304761. PMID 2437586.

3.   O'Donovan N, Galvin M, Morgan JG (1999). "Physical mapping of the CXC chemokine locus on human chromosome 4". Cytogenet. Cell Genet. 84 (1–2): 39–42. doi:10.1159/000015209. PMID 10343098.

4.      Askarieh G, Alsiö A, Pugnale P, Negro F, Ferrari C, Neumann AU, Pawlotsky JM, Schalm SW, Zeuzem S, Norkrans G, Westin J, Söderholm J, Hellstrand K, Lagging M (May 2010). "Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C". Hepatology 51 (5): 1523–30. doi:10.1002/hep.23509. PMID 20186843.